MeiraGTx Holdings PLC (NASDAQ:MGTX – Get Free Report) CEO Alexandria Forbes sold 62,000 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.17, for a total value of $568,540.00. Following the completion of the sale, the chief executive officer owned 1,387,695 shares in the company, valued at approximately $12,725,163.15. The trade was a 4.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Alexandria Forbes also recently made the following trade(s):
- On Tuesday, March 24th, Alexandria Forbes sold 62,000 shares of MeiraGTx stock. The stock was sold at an average price of $7.41, for a total value of $459,420.00.
MeiraGTx Trading Down 2.9%
Shares of NASDAQ MGTX traded down $0.27 during midday trading on Tuesday, hitting $9.13. The company’s stock had a trading volume of 3,016,935 shares, compared to its average volume of 657,565. The business’s 50 day moving average is $8.96 and its two-hundred day moving average is $8.28. MeiraGTx Holdings PLC has a 12-month low of $4.82 and a 12-month high of $11.85. The firm has a market cap of $845.53 million, a P/E ratio of -6.17 and a beta of 1.23.
Institutional Trading of MeiraGTx
Institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its position in shares of MeiraGTx by 43.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock worth $31,000 after purchasing an additional 1,466 shares in the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of MeiraGTx in the 3rd quarter worth $33,000. Tower Research Capital LLC TRC boosted its position in shares of MeiraGTx by 390.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,797 shares of the company’s stock worth $57,000 after purchasing an additional 7,005 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of MeiraGTx in the 4th quarter worth $94,000. Finally, Abel Hall LLC acquired a new stake in MeiraGTx during the 4th quarter worth about $98,000. Institutional investors and hedge funds own 67.48% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts have commented on the company. Piper Sandler raised their price objective on MeiraGTx from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, April 22nd. Bank of America raised their price objective on MeiraGTx from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, March 27th. Weiss Ratings restated a “sell (d-)” rating on shares of MeiraGTx in a report on Tuesday, April 21st. Chardan Capital restated a “buy” rating and set a $35.00 price objective on shares of MeiraGTx in a report on Friday, March 27th. Finally, Royal Bank Of Canada raised their price objective on MeiraGTx from $24.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, MeiraGTx has an average rating of “Moderate Buy” and a consensus price target of $25.83.
Read Our Latest Stock Report on MGTX
MeiraGTx Company Profile
MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.
The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.
Featured Stories
- Five stocks we like better than MeiraGTx
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
